Meta Biomed Co. Ltd (059210) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Meta Biomed Co. Ltd stock KRW 6,997, price KRW 3,450, upside +102.8%, quality 35 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 1,964 KRW – 6,383 KRW · fair‑value band 4,898 KRW – 9,096 KRW · the 3,450 KRW price screens below the 6,997 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Meta Biomed Co. in your weekly email
Every Wednesday you see whether Meta Biomed Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials.
Show moreShow less
It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products, as well as ultrasonic imaging diagnosis devices.
The company was formerly known as Metadental Co., Ltd. and changed its name to Meta Biomed Co., Ltd. in 2001. Meta Biomed Co., Ltd. was founded in 1990 and is headquartered in Cheongju, South Korea.
Stock analysis
Meta Biomed Co. Ltd (059210) currently trades at 3,450 KRW, while our model-based Fair Value estimate is 6,997 KRW, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 10,562 KRW per share, and 13 of the 16 models we run sit above the 3,450 KRW price.
Bear case: the Asset-Based group reads lowest at 873.74 KRW, and 3 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 4,898 KRW (bear) to 9,096 KRW (bull), the price of 3,450 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Meta Biomed Co. Ltd reported revenue of 103B KRW in FY2025 versus 58.8B KRW in FY2021, a compound +15.0%/yr. Reported net income was 11.0B KRW in FY2025, compounding +3.6%/yr from FY2021.
Key figures
Market cap 92.5B KRW (≈ $68.4M) Micro · P/S ratio 1.45 · Dividend yield 0.6% · Net margin 10.9% · Return on equity 2,568% · Return on assets (EBIT) 7.4% (5-year average) · Operating margin 9.0% · Revenue (TTM) 66.9B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 103%, 059210 screens cheaper than that median.
Fair Value models
Bear4,898 KRWFair Value 6,997 KRWBull9,096 KRW
Price 3,450 KRW · Upside +102.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income3,990 KRW4,059 KRW4,466 KRW76
EPV6,352 KRW6,995 KRW7,512 KRW74
ROIC Compounder6,606 KRW7,777 KRW9,121 KRW72
All 16 models by family
Earnings-Based
Graham-Dodd3,181 KRW12,870 KRW17,510 KRW64
Lynch FV3,215 KRW4,593 KRW5,971 KRW61
PEG = 1.03,215 KRW4,593 KRW5,971 KRW57
EPV6,352 KRW6,995 KRW7,512 KRW74
Dividend Discount
Gordon GGM194.88 KRW318.54 KRW406.09 KRW69
DDM Multi-Stage194.88 KRW305.76 KRW343.39 KRW67
Multiples
P/E Multiple7,718 KRW10,290 KRW12,863 KRW63
P/S Multiple5,964 KRW7,952 KRW9,939 KRW58
P/B Multiple5,076 KRW6,768 KRW8,460 KRW55
EV/EBIT10,605 KRW14,481 KRW18,358 KRW66
EV/EBITDA11,010 KRW15,022 KRW19,034 KRW67
EV/Revenue7,275 KRW10,833 KRW14,390 KRW53
Asset-Based
NCAV (Graham)576.67 KRW873.74 KRW1,092 KRW54
Economic Profit
Residual Income3,990 KRW4,059 KRW4,466 KRW76
ROIC Compounder6,606 KRW7,777 KRW9,121 KRW72
Growth Earnings
Growth-Adj P/E5,762 KRW8,232 KRW10,701 KRW67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.9%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.7.9% vs 30.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 21%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2280 stocks
Beats the sector median on 9/11 measures
Overall it ranks above its sector peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+102.8% · Top 25%
Profitability
Return on assets5.9% · Above median
Net margin (12 months)10.9% · Above median
Operating margin (12 months)9.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)40.4% · Top 25%
Dividend yield (12 months)0.6% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Meta Biomed Co. Ltd (059210) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 6,997 KRW versus a price of 3,450 KRW, about +103% upside (undervalued).
What is the fair value of 059210?
Our model-based fair value for Meta Biomed Co. Ltd is 6,997 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,450 KRW.
What is the quality score of 059210?
Meta Biomed Co. Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meta Biomed Co. Ltd (059210)?
Our model-based price target is the fair value of 6,997 KRW (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 4,898 KRW, optimistic scenario 9,096 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Meta Biomed Co. Ltd stock forecast for 2026?
Our models put fair value at 6,997 KRW, about +103% upside versus a price of 3,450 KRW (undervalued). Cautious scenario 4,898 KRW, optimistic scenario 9,096 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Meta Biomed Co. Ltd (059210)?
Meta Biomed Co. Ltd reported trailing-twelve-month revenue of about 66.9B KRW (latest available figure, as of Nov 9, 2026).
Does Meta Biomed Co. Ltd pay a dividend?
Meta Biomed Co. Ltd currently shows a dividend yield of 0.62% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Meta Biomed Co. Ltd (059210)?
Meta Biomed Co. Ltd has a dividend yield of 0.6%. A dividend has been paid every year since at least 2008. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What is the intrinsic value of Meta Biomed Co. Ltd (059210)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meta Biomed Co. Ltd it is 6,997 KRW per share (as of Nov 9, 2026), against a price of 3,450 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Meta Biomed Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 059210 trades below its calculated fair value: price 3,450 KRW, fair value 6,997 KRW, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 059210?
No. The price is what the market pays today (3,450 KRW); the fair value is what the company's own numbers justify (6,997 KRW). For Meta Biomed Co. Ltd the two are 3,547 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Meta Biomed Co. Ltd worth?
The market values Meta Biomed Co. Ltd at about 92.5B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,450 KRW; our models calculate a fair value of 6,997 KRW per share.
What do the bullish and bearish scenarios say about 059210?
Our models span a range for Meta Biomed Co. Ltd: cautious scenario 4,898 KRW, base 6,997 KRW, optimistic 9,096 KRW per share (as of Nov 9, 2026, price 3,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Meta Biomed Co. Ltd (059210)?
Balance-sheet figures for Meta Biomed Co. Ltd (as of Nov 9, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 059210 from its 52-week high?
Meta Biomed Co. Ltd trades at 3,450 KRW, about 43% below its 52-week high of 6,090 KRW and 4% above the low of 3,320 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 6,997 KRW is for.
Which stocks are comparable to Meta Biomed Co. Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Sewoon Medical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meta Biomed Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 3,450 KRW, calculated fair value 6,997 KRW (+103%), Quality Score 35/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 059210 calculated?
We run Meta Biomed Co. Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6,997 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Meta Biomed Co. Ltd currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meta Biomed Co. Ltd (059210)?
The closing price on Nov 9, 2026 was 3,450 KRW. Our model-based fair value is 6,997 KRW, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meta Biomed Co. Ltd right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (4,898 KRW). The market is more pessimistic than our downside scenario. A fairly wide model range (4,898 KRW to 9,096 KRW) leaves room in how you read the outcome.
Key figures of Meta Biomed Co. Ltd
How large is the market capitalisation of Meta Biomed Co. Ltd (059210)?
The market capitalisation of Meta Biomed Co. Ltd is 92.5B KRW (≈ $68.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meta Biomed Co. Ltd (059210)?
The price-to-sales ratio of Meta Biomed Co. Ltd is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Meta Biomed Co. Ltd (059210)?
The dividend yield of Meta Biomed Co. Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Meta Biomed Co. Ltd (059210)?
The net margin of Meta Biomed Co. Ltd is 10.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meta Biomed Co. Ltd (059210)?
The return on equity (ROE) of Meta Biomed Co. Ltd is 2,568% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meta Biomed Co. Ltd (059210)?
On an EBIT basis the return on assets of Meta Biomed Co. Ltd is 7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meta Biomed Co. Ltd (059210)?
The operating margin of Meta Biomed Co. Ltd is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meta Biomed Co. Ltd (059210)?
Revenue at Meta Biomed Co. Ltd is growing +40.4% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Meta Biomed Co. Ltd (059210)?
Earnings per share at Meta Biomed Co. Ltd are growing +45.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Meta Biomed Co. Ltd (059210) generate?
The free cash flow of Meta Biomed Co. Ltd is −628M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Meta Biomed Co. Ltd (059210) carry?
The net debt of Meta Biomed Co. Ltd is 24.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Meta Biomed Co. Ltd in the live analysis
One click puts Meta Biomed Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026